Disclosed is a pharmaceutical composition as a tablet formulation, comprising by weight/weight percent: 25-29% of cabozantinib (N-[4-[(6,7-dimethoxy-quinolin-4-yl)oxy]phenyl]-N&rsquo；-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide)； microcrystalline cellulose； 40-44% anhydrous lactose； 2-4% hydroxypropyl cellulose； 2-8% croscarmellose sodium； 0.1-0.4% colloidal silicon dioxide； and 0.7-0.9% magnesium stearate. Cabozantinib may be in the form of the free base, or a pharmaceutically acceptable salt such as the malate salt, and which may be in crystalline or amorphous form. Also disclosed is a process for manufacturing a pharmaceutical composition as defined above, comprising the steps of: a. delumping unmilled cabozantinib； b. premixing the delumped cabozantinib with microcrystalline cellulose, anhydrous lactose and croscarmellose sodium to form a binder solution； c. wet high shear granulation of the binder solution to produce wet granules； d. wet screening of the wet granules to produce wet screened granules； e. fluid bed drying of the wet screened granules to produce dried granules； f. dry milling of the dried granules to produce dried milled granules； g. blending the dried milled granules with colloidal silicon and croscarmellose to produce an extragranular blend； h. lubricant blending of the extragranular blend and magnesium stearate to produce a final blend； i. tablet compression of the final blend to form an uncoated core tablet； and optionally j. film coating of the uncoated core tablet, such as with a film coating composition comprising iron oxide yellow containing hypromellose, titanium dioxide, and triacetin.
